Cyberonics, Inc.

  • Next Leaders in Technology and Health Care

    By Declan Fallon - August 12, 2013 | Tickers: AKAM, CYBX, MRK

    Health Care and Technology stocks have offered the best reaction to earnings in the current quarter. The performance of stocks from the two sectors offer an interesting divergence between defensive health care and cyclical technology. This diversity offers good news for investors looking for the rally to continue. A time for worry is when buyers concentrate on defensive stocks at the expense of more speculative issues. However, the overall market more »

  • Are These Wednesday Post-Earnings Movers a Buy?

    By Brian Nichols - June 7, 2013 | Tickers: AMBA, BOBE, CYBX

    The medical device company Cyberonics (NASDAQ: CYBX) traded higher by 5.24% this past Wednesday after slightly beating Q1 expectations, recording revenue growth of 19% year-over-year. In addition, the company increased its guidance, which was significantly greater than Street estimates.

    Cyberonics markets and develops the Vagus Nerve Stimulation (VNS) Therapy system for refractory epilepsy and treatment-resistant depression. The company has seen substantial growth for the last five years, but many more »

  • Healthcare-Focused Hedgie Bullish on These Stocks

    By Meena Krishnamsetty - April 18, 2013 | Tickers: CYBX, ONXX, QCOR, UTHR, VPHM

    To say that William Leland Edwards of Palo Alto Investors invests heavily in healthcare stocks would be, well, a bit of an understatement. The fund’s positions read like a pharmaceutical sales rep’s resume, with the top five positions, more than 50% of the entire portfolio, all coming from the biopharmaceutical sector. Mr. Edwards has no medical training and does not hold a degree in biology or chemistry. But more »

  • Healthcare-Focused Hedgie Bullish On These Stocks

    By Meena Krishnamsetty - April 16, 2013 | Tickers: CYBX, ONXX, QCOR, UTHR, VPHM

    To say that William Leland Edwards of Palo Alto Investors invest heavily in healthcare stocks would be, well, a bit of an understatement. The fund’s positions read like a pharmaceutical sales rep’s resume, with the top five positions, more than 50% of the entire portfolio, all coming from the biopharmaceutical sector. Mr. Edwards has no medical training and does not hold a degree in biology or chemistry. But more »

  • New Stocks in Bill Miller’s $5.7 Billion Fund

    By Meena Krishnamsetty - March 18, 2013 | Tickers: CYBX, EXPD, FB, FLTX, RLGY

    Bill Miller of Legg Mason Capital Management must comply with the same SEC regulations that all 400+ of the other hedge funds we track comply with as well, including the dissemination of a quarterly holdings disclosure known as a 13F. We pay close attention to these filings, as we have found some profitable tell-tale moves by smart money managers that retail investors can make use of. Our small-cap strategy, based more »

  • Three Future Winners You Should Look At

    By Rupert Hargreaves - March 10, 2013 | Tickers: CTB, CYBX, SONC

    It can be hard to pick future winners. In fact, it is almost impossible to consistently pick small cap stocks that are destined for greatness. However, based on vigorous screening criteria, I have picked three stocks that I believe are destined for greatness, based on their current financial information.

    I have been searching for future winning equities based on the following criteria:

    1. Small market cap. – greater than $300 million but more »
  • An Upbeat Investment for VNS Therapy

    By Josef Ray Dagatan - December 10, 2012 | Tickers: CYBX, HOLX, MDT, STJ

    It is the seventh consecutive quarter that Cyberonics (NASDAQ: CYBX) has reported a major increase in their income and this has been translating well for the company in terms of stock price. Yearly revenue reports from Cyberonics also project notably outstanding results with a 4-year upward trend in profits. With this excellent performance exhibited by Cyberonics in the market, and with recent developments and innovations by the company in the more »

  • This Hedge Fund's Picks Have Returned 20% Two Straight Quarters

    By Meena Krishnamsetty - November 6, 2012 | Tickers: AUXL, CYBX, MRX, ONXX, VPHM

    We track over 400 funds and investors, and have calculated the value-weighted returns for all funds in the 1500 largest stocks, while compiling a list of the top performing funds for the first three quarters of 2012. The returns are based on the fund’s 13F long positions only, as we do not have access to their short positions.

    Palo Alto has done it again, finishing in the top five more »

  • Hedge Fund Palo Alto’s Top Stock Picks

    By Meena Krishnamsetty - September 19, 2012 | Tickers: CYBX, MDT, ONXX, STJ, SYK

    Palo Alto Investors, managed by William Leland Edwards, was one of the most successful hedge funds last quarter, at least in terms of returns generated, gaining 26.2% between March 31st and June 30th. Now, it’s worth mentioning that we can only track Palo Alto’s 13F portfolio, i.e. the quarterly positions the fund reports to the SEC, but a return in the twenties is impressive more »

  • Two Stocks Bucking the Selling

    By Declan Fallon - June 15, 2012 | Tickers: AUXL, CYBX, MDT

    Since the start of May, when sellers hit the market there is a sense of looking at it through the fingers of your hand so difficult is it to gauge how much damage they will do.  However, there are stocks - few and far between - which have tried to buck this trend.  Two stocks which have enjoyed above average buying are Auxilium Pharmaceuticals (NASDAQ: AUXL) and Cyberonics Inc (NASDAQ: CYBX).

    Auxilium more »

  • 4 Biotech Gems with Long-Term Bullish Potential

    By Streetwise Reports - June 4, 2012 | Tickers: BTX, CLDX, CYBX, GERN, OMER

    By George S. Mack, The Life Sciences Report

    For more than 22 years WBB Securities Founder and Managing Partner Stephen Brozak has been in the securities business where he has done everything from sales and management to investment banking and performing as a sellside analyst. Armed with an MBA from Columbia University and his experience as retired Lieutenant Colonel from the U.S. Marine Corps, Brozak is goal-driven with an more »